Consolidated Entities - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 282,890		$ 246,487	[1]
Receivables from collaborative arrangements	88,974		93,931	[1]
Prepaid expenses and other current assets	1,069		1,640	[1]
Equity and long-term investments	519,325		438,258	[1]
Total assets	1,088,290		999,570	[1]
Liabilities and LLC Members' Equity
Current liabilities	3,804		6,110	[1]
Total liabilities and stockholders' equity	1,088,290		999,570	[1]
Income statements
Royalty revenue from a related party	85,518	$ 78,678
Operating expenses	6,035	2,563
Income from operations	79,483	76,115
Other income (expense), net	(433)	68
Changes in fair values of equity and long-term investments, net	55,045	21,915
Net income	109,695	78,952
Theravance Respiratory Company, LLC
Assets
Cash and cash equivalents	28,444		38,081
Receivables from collaborative arrangements	22,084		24,946
Prepaid expenses and other current assets	1		0
Equity and long-term investments	22,869		16,959
Total assets	73,398		79,986
Liabilities and LLC Members' Equity
Current liabilities	640		508
LLC members' equity	72,758		79,478
Total liabilities and stockholders' equity	73,398		$ 79,986
Income statements
Royalty revenue from a related party	22,084	16,135
Operating expenses	3,281	271
Income from operations	18,803	15,864
Other income (expense), net	0	36
Changes in fair values of equity and long-term investments, net	(483)	0
Net income	$ 18,320	$ 15,900

[1] Consolidated balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements.